Notch Therapeutics
Caroline Stout is the current Director at Notch Therapeutics. Prior to this, they were with Affinivax Inc., and before that they were with Neogene Therapeutics. Caroline has also been with Neurogene, Inc. and Panacea Acquisition Corp. II. Caroline Stout has been in the field for over 15 years and has experience in a variety of positions.
Caroline Stout attended Georgetown University, where they received a BA in Economics (Honors), Pre-Med, Cognitive Science. Caroline then went on to complete their Macroeconomics degree at The London School of Economics and Political Science (LSE). Caroline finished their education at Duke University, where they earned a Philosophy degree. Caroline also holds a High School Diploma from The Potomac School. In addition, Caroline has a certification from FINRA in Series 79, Limited Representative - Investment Banking.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Notch Therapeutics
Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.